COVAX: CEPI's response to COVID-19
CEPI, Gavi and the WHO have launched COVAX to ensure equitable access to COVID-19 vaccines and end the acute phase of the pandemic by the end of 2021.
CEPI, Gavi and the WHO have launched COVAX to ensure equitable access to COVID-19 vaccines and end the acute phase of the pandemic by the end of 2021.
CEPI wants to galvanise the development of new vaccines against diseases we know could cause the next devastating epidemic.
The estimated annual global cost of moderately severe to severe pandemics
The number of diseases WHO identified as public health risks due to epidemic potential and lack of biomedical countermeasures
The minimum average cost for progressing one vaccine against each of WHO’s 11 priority epidemic infectious diseases
CEPI (pronounced 'seppy') aims to stimulate and accelerate the development of vaccines against emerging infectious diseases and enable access to these vaccines for people during outbreaks.
Ahmedabad, India (Paula Bronstein/Getty Images Reportage)